Heartland
The CBD Bandwagon Has a Comfy Seat
It’s ok to jump on the CBD bandwagon for your health! If it works for hundreds and thousands of people, why won’t it work for you?

It’s more than ok to jump on the bandwagon for your health. If it works for hundreds and thousands of people, why won’t it work for you? Bandwagons are fun and cool anyway as long as the cause behind them is right.
The FACT is CBD is not a placebo. Every human body is full of receptors and enzymes involved in pain sensation, appetite, memory, and mood. The psychoactive chemical in cannabis, THC (Δ(9)-tetrahydrocannabinol) was deemed illegal in the 1960s. 20-25 years later, scientists discovered the Endocannabinoid System (ECS) and the value of cannabinoids, such as CBD (Cannabidiol), to that system.
The more and more we research CBD, the more beneficial links between CBD and body systems we find. Thousands are lining up to tell just how cannabis assisted with their well-being and reducing their pain and anxiety. It goes as far as diminishing seizures, aiding sleep, and subsiding pain. It should not be seen as a cure-all. Sometimes people get the wrong idea when taking CBD or even worse, have been told that it doesn’t work.
The only way to find truth in information like that is to find out for yourself. You must find a reputable distributor and someone educated enough to lead you in the right direction. You need to know there are multiple routes for ingestion, and not all routes are for everyone. You do not need to be a smoker to consume CBD. Just because the hemp plant is a cousin of the marijuana plant, does not mean you are going to be high.
Sublingual tinctures or oils are the most popular and most thorough way to take CBD. Taking sublingually may not be the best route for some medications; it is a very effective way to take CBD. Ingesting CDB sublingually essentially bypasses the entire digestive system as it can enter the blood within minutes. I should mention that all sublingual tinctures are not created equal. CBD oil that carries a MCT (coconut), olive, hemp seed oil, etc., will take more time for the CBD to be absorbed. It takes the body’s ECS longer to distribute the CBD. A faster absorbing sublingual that still absorbs under the tongue is known as ‘water-soluble,’ meaning, it can mix with water, unlike oil, and therefore will absorb into the body faster. In some cases can still take a few days.
I like to think that taking a sublingual is the ‘Final Step’ when taking CBD. There are much faster routes that may give much relief, but it is not something that will last for the entire day. Smoking and vaping CBD can provide instant relief but only last an hour or two. Edibles may take up to 2 hours to absorb (some say much quicker relief) but only last 3 or 4 hours. When starting to take CBD, I recommend taking both. This way, you will get relief right away, while you wait on a CBD tincture to find your ECS and start doing its job.
Find a CBD route for you. And everyone is different, so you can explore all the types of CBD and ways to take it. The fun part about products other than sublinguals (in the beginning) are take AS NEEDED. They work with your body’s natural rhythm and can help you any time of the day. Take it in the morning for pain and anxiety relief, and take it at night for sleep.
Madison
Madison@cltcbd.com – Charlotte CBD
Source: https://cltcbd.com/blogs/news/the-cbd-bandwagon-has-a-comfy-seat
Heartland
The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects,…

Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects, including memory, pain, reproduction, bone remodeling or immunity, to name a few. Unsurprisingly, given these broad physiological effects, alterations of the ECS have been found in different diseases, including cancer. In recent years, the medical use of cannabis has been approved in different countries for a variety of human conditions. However, the use of these compounds, specifically as anticancer agents, remains controversial. Studies have shown that cannabinoids do have anticancer activity in different tumor types such as breast cancer, melanoma, lymphoma and adult brain cancer. Specifically, phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) has been shown to induce apoptosis and inhibit proliferation of adult cancer cells, as well as modulate angiogenesis and metastasis. Despite increasing evidence that cannabinoids elicit antitumor effects in adult cancers, there is minimal data available on their effects in children or in pediatric cancers despite public and clinical demand for information. Here we describe a comprehensive and critical review of what is known about the effects of cannabinoids on pediatric cancers, highlight current gaps in knowledge and identify the critical issues that need addressing before considering these promising but controversial drugs for use in pediatric oncology.
Keywords: CBD; THC; cannabidiol; cannabinoid; childhood cancer; medical cannabis; pediatric oncology; Δ9-tetrahydrocannabinol.
Heartland
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been…

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB1), type two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.
Keywords: Cannabis; multitarget; phytocannabinoids (THC and CBD); receptors; terpenes.
Heartland
Pervasive cropland in protected areas highlight trade-offs between conservation and food security
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use…

. 2021 Jan 26;118(4):e2010121118.
doi: 10.1073/pnas.2010121118.
Affiliations
Item in Clipboard
Proc Natl Acad Sci U S A. .
Abstract
Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use our global synthesis cropland dataset to quantify cropland in protected areas globally and assess their relationship to conservation aims and socio-environmental context. We estimate that cropland occupies 1.4 million km2 or 6% of global protected area. Cropland occurs across all protected area management types, with 22% occurring in strictly protected areas. Cropland inside protected areas is more prevalent in countries with higher population density, lower income inequality, and with higher agricultural suitability of protected lands. While this phenomenon is dominant in midnorthern latitudes, areas of cropland in protected areas of the tropics and subtropics may present greater trade-offs due to higher levels of both biodiversity and food insecurity. Although area-based targets are prominent in biodiversity goal-setting, our results show that they can mask persistent anthropogenic land uses detrimental to native ecosystem conservation. To ensure the long-term efficacy of protected areas, post-2020 goal setting must link aims for biodiversity and human health and improve monitoring of conservation outcomes in cropland-impacted protected areas.
Keywords: CBD; area-based targets; conservation; food security; protected areas.
Conflict of interest statement
The authors declare no competing interest.
References
-
- Klein Goldewijk K., Beusen A., Doelman J., Stehfest E.. New anthropogenic land use estimates for the holocene: HYDE 3.2. Earth Syst. Sci. Data. 2017;9:927–953.
-
- Barrett C. B.. Measuring food insecurity. Science. 2010;327:825–828.
-
- Fogel R. W.. The Escape from Hunger and Premature Death, 1700-2100: Europe, America, and the Third World. 2004.
-
- Crist E., Mora C., Engelman R.. The interaction of human population, food production, and biodiversity protection. Science. 2017;356:260–264.
-
- Pimm S. L., Vijay V.. Population, Agriculture, and Biodiversity: Problems and Prospects. 2020;365.
-
News1 week ago
Pure Harvest Bolsters Corporate Team with Key Additions
-
Heartland6 days ago
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
-
Heartland1 week ago
Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
-
Heartland1 week ago
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
-
Heartland1 week ago
Novamind Appoints Chuck Rifici to its Board of Directors
-
Uncategorized1 week ago
Sundial Announces the Launch of Premium Concentrates Products Under its Top Leaf Brand
-
Heartland1 week ago
Can You Treat COVID-19 With CBD and Reduce Mortality Rates? A New Israeli Research Believes You Can!
-
Uncategorized5 days ago
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors